UPDATE : Friday, December 6, 2019
‘Kolon might have fabricated data to get Invossa approval’ by Jeong Sae-im 2019-04-16 11:07
All Invossa products contained 293 cells, Kolon confirms by Jeong Sae-im 2019-04-15 11:31
Invossa license won’t be revoked: Kolon CEO by Jeong Sae-im 2019-04-12 11:40
Regulator, Kolon rebuked for slow response to Invossa problem by Jeong Sae-im 2019-04-11 14:46
Patients may file class-action lawsuit against Kolon for mislabeling Invossa by Jeong Sae-im 2019-04-10 14:41
Hanmi, Enzychem challenge Amgen in neutropenia treatment by Jeong Sae-im 2019-04-09 12:15
Dong-A ST’s investigational drug posts positive study results by Jeong Sae-im 2019-04-08 16:00
Kolon’s foreign partners await cell analysis results by Jeong Sae-im 2019-04-08 14:28
Kolon Life Science criticized for poor quality control on Invossa by Jeong Sae-im 2019-04-05 12:27
‘Invossa, first treatment to have used cancerous cell lines’ by Jeong Sae-im 2019-04-04 15:24
[Special] MSD Korea makes wrong excuse on external monitoring by Jeong Sae-im 2019-04-03 16:59
‘Paternity testing’ would have prevented Invossa debacle by Jeong Sae-im 2019-04-02 15:27
[Special] MSD Korea asks monitoring agents to record talks ‘discreetly’ by Jeong Sae-im 2019-04-02 14:45
[Special] Why doctors got upset with MSD Korea’s monitoring program by Jeong Sae-im 2019-04-01 14:22
JW Life Science wins nod for 3rd-generation nutrient infusion in Europe by Jeong Sae-im 2019-03-27 16:16
‘Remimazolam has fewer side effects than propofol’ by Jeong Sae-im 2019-03-27 15:05
Huons Medicare wins CE certification for medical disinfectant by Jeong Sae-im 2019-03-27 13:55
‘MSD Korea excessively monitors workers, collects client info without consent’ by Jeong Sae-im 2019-03-22 13:49
Health minister asks AI-backed drug-developing support center to go bolder by Jeong Sae-im 2019-03-21 14:44
Il-yang, Hanmi achieve robust sales growth in China by Jeong Sae-im 2019-03-19 11:21
Back to Top